D. Boral Capital Begins Coverage on CERo Therapeutics (NASDAQ:CERO)

Research analysts at D. Boral Capital started coverage on shares of CERo Therapeutics (NASDAQ:CERO) in a report issued on Tuesday,Benzinga reports. The firm set a “buy” rating and a $11.00 price target on the stock.

CERo Therapeutics Stock Performance

CERO opened at $0.80 on Tuesday. The stock’s 50 day simple moving average is $1.08 and its 200 day simple moving average is $6.07. CERo Therapeutics has a 1-year low of $0.53 and a 1-year high of $171.00.

Hedge Funds Weigh In On CERo Therapeutics

A number of institutional investors have recently modified their holdings of CERO. Parallel Advisors LLC acquired a new position in shares of CERo Therapeutics during the 1st quarter valued at about $161,000. Avantax Planning Partners Inc. raised its position in shares of CERo Therapeutics by 89.9% in the 4th quarter. Avantax Planning Partners Inc. now owns 2,585,151 shares of the company’s stock worth $155,000 after buying an additional 1,224,021 shares during the period. Finally, ARCH Venture Management LLC boosted its holdings in CERo Therapeutics by 550.4% in the fourth quarter. ARCH Venture Management LLC now owns 9,393,561 shares of the company’s stock valued at $564,000 after acquiring an additional 7,949,265 shares during the last quarter. Institutional investors and hedge funds own 29.64% of the company’s stock.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.